Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Redbud Closes $10 Million Round for China-US Clinical CRO Services

publication date: Sep 12, 2022

Redbud Medicine, a Beijing-Maryland clinical CRO, closed a $10 million Series A round to support its cross-border China-US operations. The company aims to supply clinical CRO services in both countries, allowing biopharma companies to have a single CRO operator that is fully capable of conducting trials for the two markets. Further, by using intelligent technologies, Redbud says it optimizes and accelerates every clinical trial step, lowering the cost and accelerating the process. The round included MING Bioventures Capital, Delian Capital and an Angel round investor Hongfeng Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital